Cutaneous graft-versus-host disease incidence is similar in haploidentical and matched unrelated hematopoietic transplant recipients: A retrospective cohort study - 09/11/20
Abstract |
Background |
Cutaneous graft-versus-host disease (GVHD) is common after hematopoietic cell transplants. Haploidentical transplants (Haplo) have historically higher rates of GVHD with overall outcomes improved with the use of posttransplant cyclophosphamide. Specific cutaneous outcomes have not been explored in haploidentical versus matched unrelated donor (MUD) transplants.
Objective |
We sought to examine the incidence of GVHD in MUD and Haplo transplants.
Methods |
This is a retrospective cohort study of patients' records that received MUD or Haplo transplants between 2010 and 2015 with determination of GVHD severity and features by one investigator.
Results |
The Haplo cohort included more minorities (22.7% vs 6.8%; P < .001). The incidence of acute cutaneous GVHD was similar (Haplo 47.7% [95% confidence interval {CI} 37.0-58.6%] vs MUD 42.6% [95% CI 37.9-47.3%]; P = .41). Chronic GVHD was also similar (Haplo 17.1% [95% CI 9.9-26.6%] vs MUD 12.8% [95% CI 9.9-16.3%]; P = .31). The Haplo group had lower rates of sclerosis (13.3% [95% CI 1.7-4.05%] vs 50.9% [95% CI 37.3-64.4%]; P = .0095). Other secondary outcomes showed no difference.
Limitations |
Severity of GVHD was determined retrospectively and not all patients were seen by a dermatologist.
Conclusions |
No difference was observed between rates or severity of acute or chronic GVHD. Sclerosis was less common in the Haplo group.
Le texte complet de cet article est disponible en PDF.Key words : bone marrow transplant, graft-versus-host disease, haploidentical transplant, stem cell transplant
Plan
| Supported by a grant from the Mentors in Medicine Program at Washington University in Saint Louis to Dr Heberton. |
|
| Dr Anadkat has received honoraria for consulting and/or speaking engagements in the past from Adgero, Astra Zeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Biogen, Eli Lilly, Genentech, ImClone, Therakos, Xoma, and Eisai, and has served as a principal investigator for Biogen, Veloce, Xoma, Hana Biosciences, and InflamRx. The other authors have no conflicts of interest to disclose. |
|
| Reprints not available from the authors. |
Vol 83 - N° 6
P. 1654-1658 - décembre 2020 Retour au numéro
Article précédent
- Application of machine learning to determine top predictors of noncalcified coronary burden in psoriasis: An observational cohort study
- Eric Munger, Harry Choi, Amit K. Dey, Youssef A. Elnabawi, Jacob W. Groenendyk, Justin Rodante, Andrew Keel, Milena Aksentijevich, Aarthi S. Reddy, Noor Khalil, Jenis Argueta-Amaya, Martin P. Playford, Julie Erb-Alvarez, Xin Tian, Colin Wu, Johann E. Gudjonsson, Lam C. Tsoi, Mohsin Saleet Jafri, Veit Sandfort, Marcus Y. Chen, Sanjiv J. Shah, David A. Bluemke, Benjamin Lockshin, Ahmed Hasan, Joel M. Gelfand, Nehal N. Mehta
- Diffuse variants of scalp lichen planopilaris: Clinical, trichoscopic, and histopathologic features of 40 patients
- Michela Starace, Gloria Orlando, Aurora Alessandrini, Carlotta Baraldi, Francesca Bruni, Bianca Maria Piraccini
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?